{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-003071","form_type":"8-K","ticker":"TRAW","cik":"0001130598","company_name":"Traws Pharma, Inc.","filed_at":"2026-01-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.597054+00:00","generated_at":"2026-05-16T10:33:58.132503+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Traws Pharma files IND for flu drug TXM; ratutrelvir beats Paxlovid on symptom resolution in interim study","bullets":["IND filed with FDA for tivoxavir marboxil (TXM) for influenza; final step for BARDA stockpile consideration.","Interim Phase 2 data: ratutrelvir showed faster symptom resolution vs Paxlovid (12 vs 14 days, p<0.014).","No viral rebound in ratutrelvir arm vs one in Paxlovid; fewer adverse events (7.6% mild dyspepsia vs 30% in comparator).","Ratutrelvir showed consistent safety and efficacy in Paxlovid-ineligible patients (13 patients).","Full study enrollment expected in January 2026; 95% of 90 patients enrolled."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-003071","json":"https://secwatch.observer/filing/0001104659-26-003071.json","markdown":"https://secwatch.observer/filing/0001104659-26-003071.md","text":"https://secwatch.observer/filing/0001104659-26-003071.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1130598/000110465926003071/0001104659-26-003071-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1130598/000110465926003071/tm263039d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T10:33:58.132503+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}